Recruiting PHASE3 Overweight

Clinical trial for Overweight

Official title Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight

ClinicalTrials.gov ID: NCT07770841

What this study is testing

What is Semaglutide?

Semaglutide is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for overweight.

Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.

What it's testing
The purpose of this study is to see how oral semaglutide, when taken in lower doses help lowering of body weight in participants with excess body weight when compared to 'dummy' tablets (placebo). Results from this study will help select the most optimal lower dose of oral semaglutide that can be used for treating participants living with overweight or obesity.
  • Phase 3: a large, late-stage study
  • You might receive a placebo (an inactive treatment) instead of the study drug.

A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.

Who can take part

Ages 18 and older

You may be able to join if

  • Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study...
  • Female or male (sex at birth).
  • Age 18 years or above at the time of signing the informed consent.
  • Body mass index (BMI) of
  • ≥ 27.0 kilogram per square meter (kg/m\^2) with the presence of at least one weight-related comorbidity including, but not limited to, hypertension...

You likely can't join if

  • A self-reported change in body weight greater than (\>) 5% within 90 days before screening irrespective of medical records.
  • HbA1c ≥ 6.5% (48 millimoles per mole [mmol/mol]) as measured by the central laboratory at screening.
  • Consistent use of glucagon like peptide-1 (GLP-1) receptor agonists, including medication with glucagon like peptide-1 receptor agonist (GLP-1 RA)...
See the full eligibility criteria
Who can join
  • Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
  • Female or male (sex at birth).
  • Age 18 years or above at the time of signing the informed consent.
  • Body mass index (BMI) of
  • ≥ 27.0 kilogram per square meter (kg/m\^2) with the presence of at least one weight-related comorbidity including, but not limited to, hypertension, dyslipidaemia, obstructive sleep apnoea or CV disease. OR
  • ≥ 30.0 kg/m\^2.
  • History of at least one self-reported unsuccessful dietary effort to lose body weight.
What rules you out
  • A self-reported change in body weight greater than (\>) 5% within 90 days before screening irrespective of medical records.
  • HbA1c ≥ 6.5% (48 millimoles per mole [mmol/mol]) as measured by the central laboratory at screening.
  • Consistent use of glucagon like peptide-1 (GLP-1) receptor agonists, including medication with glucagon like peptide-1 receptor agonist (GLP-1 RA) activity like dual GLP-1/gastric inhibitory peptide RAs, or amylin...

The study team makes the final eligibility decision.

Where it's taking place

  • Birmingham, Alabama, United States
  • Escondido, California, United States
  • Huntington Park, California, United States
  • Los Angeles, California, United States
  • Delray Beach, Florida, United States
  • Fort Myers, Florida, United States
  • Tampa, Florida, United States
  • Honolulu, Hawaii, United States
  • Louisville, Kentucky, United States
  • City of Saint Peters, Missouri, United States
  • Las Vegas, Nevada, United States
  • Corvallis, Oregon, United States
  • Philadelphia, Pennsylvania, United States
  • Spartanburg, South Carolina, United States
  • Dallas, Texas, United States
  • Winchester, Virginia, United States
  • Alken, Belgium
  • Bonheiden, Belgium
  • Brussels, Belgium
  • Ghent, Belgium

+ 38 more site(s).

Questions & answers

Do participants get paid in this trial?

This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.

How long does this study last?

The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.

Who can join this trial?

This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.

Where is this trial taking place?

Study sites include Birmingham, Alabama, United States; Escondido, California, United States; Huntington Park, California, United States; Los Angeles, California, United States; Delray Beach, Florida, United States; Fort Myers, Florida, United States and 52 more location(s). Enter your location above to see the nearest site and check your eligibility.

Explore other conditions

BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.